Additional file 2 of Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib

Additional file 2: Figure S2. Expression of surface markers of aCML neutrophils over the course of ruxolitinib therapy and correlation with migration patterns. (A) Comparison of CD15 and CD16 expression of aCML neutrophils after 2 weeks of ruxolitinib treatment (2 weeks Ruxo) after two different purification methods: density gradient centrifugation (density gradient, left) and negative magnetic isolation via MACSxpress® separation (MACS, right). (B) Changes in CD16, CD15 and fMLPR (top) as well as CXCR1 and CXCR2 (bottom) expression given as mean fluorescent intensity (mfi) of aCML neutrophils over the course of therapy. Black triangles and black solid lines indicate the aCML patient (every timepoint n = 1), while grey dots and grey dashed lines indicate the median and the grey dotted lines indicate the interquartile range of the age-matched controls (n = 5). Numbers label the specific values for receptor expression at the respective timepoint. (C-F) Correlation of receptor expression against migration upon corresponding stimulus treatment. Black triangles indicate the aCML patient (n = 1) and grey dots indicate age-matched controls (n = 5). Correlations were computed using GraphPad Prism™. Spearman r and p-value for the correlation of aCML samples are given. (C) fMLPR expression correlated against migration upon fMLPR treatment. (D) CXCR1 expression correlated against migration upon CXCL8 treatment. (E) CXCR2 expression correlated against CXCL1 treatment. (F) CXCR2 expression correlated against CXCL8 treatment.